Meta-analysis and systematic review: burosumab as a promising treatment for children with X-linked hypophosphatemia
Authors:
Open Access
- 15 August 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1414509
Abstract
Objective: The aim of this study was to evaluate the effectiveness of burosumab therapy in children with X-Linked Hypophosphatemia (XLH).Materials and methods: We systematically reviewed literature from PubMed, Web of Science, The Cochrane Library, and Embase up until January 2024, using EndNote Web for study organization. The Newcastle–Ottawa scale guided quality assessment, while Revman software was used for data analysis and visualization. Study selection, quality evaluation, and data aggregation were independently performed by three researchers.Results: The meta-analysis encompassed ten studies, including eight cohort studies that examined burosumab’s impact pre- and post-administration, and two randomized controlled trials comparing burosumab to standard therapy. The evidence from this review suggests burosumab’s superiority in managing XLH in pediatric populations, particularly in improving key biochemical markers including 1,25-dihydroxyvitamin D (1,25-(OH)2D), phosphorus, and alkaline phosphatase (ALP), alongside improvements in the renal tubular maximum reabsorption rate of phosphate to glomerular filtration rate (TmP/GFR), and significant skeletal improvements as indicated by the rickets severity score (RSS) and the 6-minute walk test (6MWT). However, the long-term safety and effects, including height and quality of life (QOL) data, remains to be elucidated.Conclusions: Burosumab has shown significant therapeutic effectiveness in treating children with XLH, highlighting its potential as a key treatment option.Keywords
Funding Information
- National Natural Science Foundation of China (82072483, 82270956)
This publication has 46 references indexed in Scilit:
- Burosumab: Current status and future prospectsBest Practice & Research Clinical Endocrinology & Metabolism, 2023
- Linear growth of children with X-linked hypophosphatemia treated with burosumab: a real-life observational studyEuropean Journal of Pediatrics, 2023
- Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical StudiesAdvances in Therapy, 2023
- Real-world effectiveness of burosumab in children with X-linked hypophosphatemic ricketsPediatric Nephrology, 2022
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary AnalysisJournal of Bone and Mineral Research, 2018
- Burosumab: First Global ApprovalDrugs, 2018
- X-linked hypophosphatemia and growthReviews in Endocrine and Metabolic Disorders, 2017
- PHEX 3′-UTR c.*231A>G Near The Polyadenylation Signal Is a Relatively Common, Mild, American Mutation That Masquerades as Sporadic or X-Linked Recessive Hypophosphatemic RicketsJournal of Bone and Mineral Research, 2014
- Phenotype Presentation of Hypophosphatemic Rickets in AdultsCalcified Tissue International, 2010
- Serum 1,25-dihydroxyvitamin D levels in subjects with X-linked hypophosphatemic rickets and osteomalaciaCalcified Tissue International, 1982